S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
pixel
pixel
Log in
ASX:HMD

HeraMED Limited (HMD.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.11
MA: A$0.11
A$0.11
52-Week Range N/A
Volume98,572 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
HeraMED Limited develops and sells pregnancy monitoring solutions for home and professional use in Australia, Europe, and Israel. The company's product is the HeraBEAT, a fetal heart rate monitor principally for use by an expectant mother to monitor their fetus' heartbeat. It is also involved in developing EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a co-development agreement with Mayo Clinic for developing platform for pregnancy homecare; cooperation agreement with Freeman Rd & PHI Group to arrange and lead clinical studies in Australia; and partnership agreement with eCare21, Inc. to integrate its technology into the eCare21 platform. HeraMED Limited was founded in 2011 and is based in Sydney, Australia.

MarketRank

Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 8 6189 1155
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$93,646.00
Book ValueA$0.02 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive HMD News and Ratings via Email

Sign-up to receive the latest news and ratings for HMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











HeraMED Limited (HMD.AX) (ASX:HMD) Frequently Asked Questions

What stocks does MarketBeat like better than HeraMED Limited (HMD.AX)?

Wall Street analysts have given HeraMED Limited (HMD.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but HeraMED Limited (HMD.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of HeraMED Limited (HMD.AX)'s key competitors?

Who are HeraMED Limited (HMD.AX)'s key executives?

HeraMED Limited (HMD.AX)'s management team includes the following people:
  • Mr. David Groberman, Co-Founder, CEO & Exec. Director
  • Mr. Tal Slonim, Co-Founder, COO & Exec. Director
  • Ms. Sivan Sadan, Chief Financial Officer
  • Mr. Michael Nenner, Chief Technology Officer
  • Henry Jordan, Head of Investor Relations
  • Mr. Ariel Laden, VP of Marketing
  • Dr. Josef Tovbin, Chief Medical Officer
  • Mr. Jonathan Hart B.Com., L.L.B., Company Sec.

What is HeraMED Limited (HMD.AX)'s stock symbol?

HeraMED Limited (HMD.AX) trades on the ASX under the ticker symbol "HMD."

How big of a company is HeraMED Limited (HMD.AX)?

HeraMED Limited (HMD.AX) has a market capitalization of $0.00 and generates $93,646.00 in revenue each year.

What is HeraMED Limited (HMD.AX)'s official website?

The official website for HeraMED Limited (HMD.AX) is www.hera-med.com.

How can I contact HeraMED Limited (HMD.AX)?

The company can be reached via phone at 61 8 6189 1155.

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.